DÄ internationalArchiveReferences

Original article

The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences

Dtsch Arztebl Int 2010; 107(17): 295-301. DOI: 10.3238/arztebl.2010.0295

Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Lieb, K; Ludwig, WD

1. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454–65. MEDLINE
2. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167–70. MEDLINE
3. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences: part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen – Teil 1: Qualitative systematische Literaturübersicht zu Einfluss auf Studienergebnisse, -protokoll und -qualität]. Dtsch Arztebl Int 2010; 107 (16): 279–85. VOLLTEXT
4. Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care 1996; 12: 209–37. MEDLINE
5. International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Updated: Oktober 2007.
6. Arbeitsgruppe Glossar im DNEbM e.V.: EbM-Glossar: Publikationsbias: Deutsches Netzwerk Evidenzbasierte Medizin e.V. Stand: 16. März 2008. Zuletzt geprüft: 22. Oktober 2009.
7. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al.: Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004; 292: 1363–4. MEDLINE
8. Pharmaceutical Research and Manufacturers of America: PhRMA Clinical Trial Registry Proposal. Zuletzt geprüft: 22. Oktober 2008.
9. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan Pharmaceutical Manufacturers Association (JPMA), Pharmaceutical Research and Manufacturers of America (PhRMA): Gemeinsame Position zur Offenlegung von Informationen zu klinischen Studien über Register und Datenbanken. Bekannt gegeben: 06. Januar 2005.
10. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y: When good drugs go bad. Nature 2007; 446: 975–7. MEDLINE
11. Chalmers I: Underreporting research is scientific misconduct. JAMA 1990; 263: 1405–8. MEDLINE
12. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan Pharmaceutical Manufacturers Association (JPMA), Pharmaceutical Research and Manufacturers of America (PhRMA): Gemeinsame Position zur Offenlegung sensibler Daten in Studienregistern. Bekannt gegeben: 5. September 2005.
13. Smith R: Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2: e138. MEDLINE
14. Bunge M, Muhlhauser I, Steckelberg A: What constitutes evidence-based patient information? Overview of discussed criteria. Patient Educ Couns 2009; Epub ahead of print. MEDLINE
15. PLoS Medicine Editors: Next stop, don’t block the doors: opening up access to clinical trials results. PLoS Med 2008; 5: e160. MEDLINE
16. Directive 2001/20/EEC of the european parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 2001; L 121: 34–44.
17. European Commission—Enterprise and Industry Directorate-General, Consumer Goods, Pharmaceuticals: Draft list of fields contained in the ’EudraCT’ clinical trials database to be included in the ’EudraPharm’ database on medicinal products and made public, in accordance with Article 57(2) of Regulation (EC) No 726/2004: www.ec.europa.eu. Public Consultation Paper. Version: 15 July 2008.
18. Mitteilung der Kommission betreffend die Leitlinie zu den Datenfeldern der in Artikel 11 der Richtlinie 2001/20/EG vorgesehenen Datenbank über klinische Versuche, die in die gemäß Artikel 57 der Verordnung (EG) Nr. 726/2004 eingerichtete Datenbank über Arzneimittel aufzunehmen sind (2008/C 168/02). Amtsblatt der Europäischen Union 2008; C 168: 3–4.
19. Kaiser J: Making clinical data widely available. Science 2008; 322: 217–8. MEDLINE
20. Verband Forschender Arzneimittelhersteller e.V. (VFA) (eds.): Ethik-Handbuch: Ethisches Verhalten bei der Zusammenarbeit der forschenden Arzneimittelhersteller mit Ärzten, Patientenorganisationen und den anderen Partnern im Gesundheitswesen. Ausgabe November 2007. Berlin: VFA, 2007.
21. Garattini S, Chalmers I: Patients and the public deserve big changes in evaluation of drugs. BMJ 2009; 338: b1025. MEDLINE
22. Ludwig W-D, Fetscher S, Schildmann J: Teure Innovationen in der Onkologie – für alle? Der Onkologe 2009; 15: 1004–14.
23. Booth CM, Tannock I: Reflections on medical oncology: 25 years of clinical trials—where have we come and where are we going? J Clin Oncol 2008; 26: 6–8. MEDLINE
24. DeAngelis CD, Fontanarosa PB: Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299: 1833–5. MEDLINE
25. Young NS, Ioannidis JP, Al-Ubaydli O: Why current publication practices may distort science. PLoS Med 2008; 5: e201. MEDLINE
e1. Katz KA, Karlawish JH, Chiang DS, Bognet RA, Propert KJ, Margolis DJ: Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. J Am Acad Dermatol 2006; 55: 814–22. MEDLINE
e2. Waldinger MD, Schweitzer DH: Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med 2008; 5: 966–97. MEDLINE
e3. Nieto A, Mazon A, Pamies R, Linana JJ, Lanuza A, Jimenez FO, et al.: Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med 2007; 167: 2047–53. MEDLINE
e4. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Ghost authorship in industry-initiated randomised trials. PLoS Med 2007; 4: e19. MEDLINE
e5. Ross JS, Hill KP, Egilman DS, Krumholz HM: Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008; 299: 1800–12. MEDLINE
e6. Zarin DA, Tse T, Ide NC: Trial Registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 2005; 353: 2779–87. MEDLINE
e7. Lott JP, Katz KA: Pharmaceutical companies’ policies and practices regarding prospective registration of dermatology-related clinical trials. Br J Dermatol 2006; 155: 635–8. MEDLINE
e8. Psaty BM, Furberg CD, Ray WA, Weiss NS: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004; 292: 2622–31. MEDLINE
e9. Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008; 299: 1813–7. MEDLINE
e10. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9. MEDLINE
e11. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM: Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009; 169: 1976–85. MEDLINE
e12. Aursnes I, Gjertsen MK: Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiol Drug Saf 2008; 17: 707–13. MEDLINE
e13. Halpern SD, Barton TD, Gross R, Hennessy S, Berlin JA, Strom BL: Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. Pharmacoepidemiol Drug Saf 2005; 14: 155–61. MEDLINE
e14. Lee K, Bacchetti P, Sim I: Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008; 5: e191. MEDLINE
e15. Rising K, Bacchetti P, Bero L: Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008; 5: e217. MEDLINE
e16. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–60. MEDLINE
e17. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326: 1171–3. MEDLINE
e18. Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361: 1963–71. MEDLINE
e19. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–5. MEDLINE
e20. von Elm E, Rollin A, Blumle A, Huwiler K, Witschi M, Egger M: Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly 2008; 138: 197–203. MEDLINE
e21. Krzyzanowska MK, Pintilie M, Tannock IF: Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003; 290: 495–501. MEDLINE
e22. Kho ME, Brouwers MC: Conference abstracts of a new oncology drug do not always lead to full publication: proceed with caution. J Clin Epidemiol 2009; 62: 752–8. MEDLINE
e23. Hole OP, Nitter-Hauge S, Cederkvist HR, Winther FO: An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results. Eur J Clin Pharmacol 2009; 65: 315–8. MEDLINE
e24. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM: Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 2009; 6: e1000144. MEDLINE
e25. Conen D, Torres J, Ridker PM: Differential citation rates of major cardiovascular clinical trials according to source of funding: a survey from 2000 to 2005. Circulation 2008; 118: 1321–7. MEDLINE
e26. Jefferson T, Di PC, Debalini MG, Rivetti A, Demicheli V: Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ 2009; 338: b354. MEDLINE
e27. Kuriya B, Schneid EC, Bell CM: Quality of pharmaceutical industry press releases based on original research. PLoS ONE 2008; 3: e2828. MEDLINE
e28. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Constraints on publication rights in industry-initiated clinical trials. JAMA 2006; 295: 1645–6. MEDLINE
e29. Henry DA, Kerridge IH, Hill SR, McNeill PM, Doran E, Newby DA, et al.: Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005; 182: 557–60. MEDLINE
e30. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457–65. MEDLINE
e31. Smith R: Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003; 326: 1202–5. MEDLINE
e32. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK: Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008; 26: 5458–64. MEDLINE
e33. Peppercorn J, Blood E, Winer E, Partridge A: Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007; 109: 1239–46. MEDLINE
e34. Patsopoulos NA, Ioannidis JP, Analatos AA: Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 2006; 332: 1061–4. MEDLINE
e35. Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA: Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer 2009; Epub ahead of print. MEDLINE
e36. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, et al.: Research Methods & Reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009; 339: b4330. MEDLINE
e37. Equator network website. Zuletzt geprüft: 8. Februar 2010